

Primary hepatic lymphoma: a retrospective, multicenter Rare Cancer Network study

Gamze Ugurluer,^{1,2} Robert C. Miller,¹ Yexiong Li,³ Juliette Thariat,⁴ Pirus Ghadjar,⁵ Ulrike Schick,⁶ Mahmut Ozsahin⁷

¹Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA;

²Department of Radiation Oncology, Acibadem Adana Hospital, Acibadem University, Adana, Turkey; ³Department of Radiation Oncology, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; ⁴Department of Radiation Oncology, Center Antoine-Lacassagne, Nice, France; ⁵Department of Radiation Oncology, Berlin Inselspital, Bern University Hospital and University of Bern, Charité Universitätsmedizin Berlin, Germany; ⁶Department of Radiation Oncology, University Hospital, Brest, France; ⁷Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Abstract

Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the *Rare Cancer Network* (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23-86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1% of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9%). Most of the patients received Chop-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens; 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59%, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70%, respectively. Multivariate analysis revealed that fever, weight loss, and normal hemoglobin level were the independent factors influencing the out-

come. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors.

Introduction

Primary hepatic lymphoma (PHL) is a rare malignancy, although secondary liver involvement in patients with advanced stages of lymphoma is common. PHL represents 0.016% of all non-Hodgkin's lymphomas and 0.4% of all extranodal lymphomas.¹ Because of the low number of reported cases, the disease is poorly understood and few clinical studies have been conducted to help elucidate the pathogenesis, variability of the clinical presentation, natural course of the disease, optimal therapy, response to therapy, and survival.^{2,3}

Regarding the exact definition of PHL, no consensus has been achieved. Some reports have been based on cases in which staging investigations failed to show extrahepatic disease, whereas others have accepted cases as being *primary* if the disease was confined to the liver at presentation.⁴ The criteria for diagnosis defined by Lei are: i) symptoms caused mainly by liver involvement at presentation; ii) absence of distant lymphadenopathy, palpable clinically at presentation or detected during staging radiologic studies; and iii) absence of leukemic blood involvement in the peripheral blood smear.⁵

The pathogenesis is not clear but several etiologic factors for PHL have been proposed such as an increased incidence of PHL in patients with hepatitis B and C virus infection and exposure to chemicals.⁶⁻⁸ Most of the patients diagnosed with PHL are middle-aged men, majority of cases are diffuse large B-cell type, and presenting complaints consists of abdominal pain, fatigue, and constitutional symptoms, hepatomegaly being frequent.⁹

Although there is little consistency in the literature regarding the treatment, options include surgery, chemotherapy, radiation therapy or combination of these modalities. The reported median survival rates vary widely in the literature, however, it is believed that the prognosis for patients with PHL is dismal, with early disease recurrence at extrahepatic sites and short survival.^{5,9}

The purpose of this study was to assess the clinical profile, outcome and prognostic factors in PHL in an attempt to gather additional information on this rare entity through the *Rare Cancer Network* (RCN).

Correspondence: Gamze Ugurluer, Acibadem University Medicine Faculty, Department of Radiation Oncology, Adana Hospital, Cumhuriyet Caddesi No: 66 01130, Seyhan, Adana, Turkey. Tel: +90.322.455.45.64; +90.532.250.91.72 Fax: +90.322.455.44.77. E-mail: gamze.ugurluer@acibadem.edu.tr

Key words: Non-Hodgkin's lymphoma, primary hepatic lymphoma, chemotherapy

Contributions: all authors have significantly contributed to and agreed on the content of the manuscript. GU and MO proposed the study for RCN, each author collected the data from their own institution, each author contributed to the analysis and interpretation of the manuscript by reviewing drafts and approved the final version to be published.

Conflict of interest: the authors declare no potential conflict of interest.

Conference presentation: Part of this paper was presented at the 57th ASTRO (American Society for Radiation Oncology) Annual Meeting, October 18-21, 2015, San Antonio, Texas, USA. This study was approved by Mayo Foundation Institutional Review Board and at each participating center independently.

Received for publication: 10 March 2016.

Accepted for publication: 13 March 2016.

This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).

©Copyright G. Ugurluer et al., 2016

Licensee PAGEPress, Italy

Rare Tumors 2016; 8:6502

doi:10.4081/rt.2016.6502

Materials and Methods

A retrospective analysis of patients with PHL diagnosed between 1977 and 2014 was performed in the framework of RCN. Seven institutions within 5 countries of the RCN group contributed cases of PHL, and 41 patients met the criteria for PHL suggested by Lei.⁵ Patients with splenic and bone marrow involvement were excluded. This study was approved by Mayo Foundation Institutional Review Board and at each participating center independently. The medical records of all patients were reviewed to identify patients and tumor characteristics, treatment details, and follow-up information. All original pathology reports were reviewed using the World Health Organization (WHO) classification of lym-

phoma. The cut-off date for the survival study was December 2014. The histologic slides were not centrally reviewed.

Survival curves were computed using the Kaplan-Meier method. The events were death irrespective of cause for overall survival (OS) and any relapse for disease-free survival (DFS), and time was measured from the date of diagnosis to the event. The lymphoma-specific survival (LSS) was calculated to the date of death related to lymphoma from the date of diagnosis. Log-rank and Wilcoxon tests were used to determine prognostic factors and assess differences between groups. Cox multiple regression analysis was done for prognostic factors having a P-value ≤ 0.25 in univariate analyses. A P-value < 0.05 was considered to be significant. The statistical analyses were performed using JMP v11 (SAS Corp., Cary, NC, USA).

Results

Patients' clinicopathological and laboratory characteristics are summarized in Table 1. Median age was 62 years (range, 23-86 years) with a male-to-female ratio of 1.9:1.0 (27/14). Median follow-up time was 116 months (range, 1-225 months). Abdominal pain or discomfort was the most common presenting symptom, and occurred in 22 patients (53.7%). The other symptoms were fatigue (22.0%), jaundice (14.6%), anorexia (14.6%), nausea and/or vomiting (17.1%). Regarding the B-symptoms, 19.5% of patients had fever, 17.1% had weight loss, and 9.8% had night sweats. Hepatomegaly was found in 17.1% of patients, and splenomegaly was less common (9.8%). Thirteen patients (31.7%) had a history of pre-existing liver disease, 6 patients had chronic hepatitis (14.6%), 4 patients with cirrhosis (9.8%), one patient had polycystic liver disease (2.4%), and 4 patients were diagnosed after liver transplantation (9.8%). The imaging modalities used evolved over time and location, most patients (63.4%) had computed tomography (CT) or ultrasonography (56.1%), and only 6 patients had positron emission tomography-CT (14.6%). The most common radiological presentation was multiple lesions (53.7%) followed by solitary lesion (36.6%), and diffuse infiltration was present in 7.3% of patients. Liver function tests, including lactate dehydrogenase, alkaline phosphatase and bilirubin, were elevated in 56.1% of patients who were tested. Hemoglobin levels in complete blood count were lower than normal in 11 patients (26.8%) who were tested. Two patients were Hepatitis B Ag positive, and 2 patients were HIV positive among patients who were tested. Bone-marrow aspiration results were recorded, and were normocellular if avail-

able (26 patients). The most common histopathological diagnosis was diffuse large B-cell lymphoma, which was observed in 27 patients (65.9%) according to the WHO classification system. Four tumors were marginal-zone B-cell lymphoma, 3 were follicular lymphoma, 2 were precursor-cell lymphoblastic lymphoma, 2 were mature T-cell lymphoma, 1

was malignant lymphoma small lymphocytic, 1 was small lymphocytic type T-cell lymphoma, and 1 was Burkitt lymphoma. Combination chemotherapy was administered to 30 patients (73.2%). Chemotherapy regimens were different according to the year of diagnosis and the center. Most of the patients received CHOP-like (cyclophosphamide, doxorubicin, vin-

Table 1. Patients' clinicopathological and laboratory characteristics.

Characteristics	No. (%)
Median age (at the time of diagnosis)	62 (range, 23-86 years)
Gender (male-to-female ratio)	1.9:1.0
Male	27 (65.9)
Female	14 (34.1)
Presenting symptoms	
Abdominal pain or discomfort	22 (53.7)
Fatigue	9 (22.0)
Jaundice	6 (14.6)
Anorexia	6 (14.6)
Nausea and/or vomiting	7 (17.1)
B symptoms	
Fever	8 (19.5)
Weight loss	7 (17.1)
Night sweats	4 (9.8)
Hepatomegaly	7 (17.1)
Splenomegaly	4 (9.8)
Pre-existing liver disease	
Chronic hepatitis	6 (14.6)
Cirrhosis	4 (9.8)
Liver transplantation	4 (9.8)
Polycystic liver disease	1 (2.4)
Radiological presentation	
Multiple lesions	22 (53.7)
Solitary lesion	15 (36.6)
Diffuse infiltration	3 (7.3)
Histopathological diagnosis	
Diffuse large B-cell lymphoma	27 (65.9)
Marginal zone B-cell lymphoma	4 (9.8)
Follicular lymphoma grade 1	3 (7.3)
Precursor cell lymphoblastic lymphoma	2 (4.9)
Mature T-cell lymphoma	2 (4.9)
Small lymphocytic type T-cell lymphoma	1 (2.4)
Malignant lymphoma small lymphocytic	1 (2.4)
Burkitt lymphoma	1 (2.4)
Treatment	
Combination chemotherapy	30 (73.2)
Radiotherapy/chemo-radiotherapy	4 (9.8)
Surgery	4 (9.8)

Table 2. Chemotherapy regimens.

Regimen	No. (%)
CHOP-like	
CHOP	8 (19.5)
R-CHOP	8 (19.5)
CHOEP	1 (2.4)
CHEP	1 (2.4)
COP	1 (2.4)
CHOP-Bleo	1 (2.4)
Others	10 (24.4)

CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, rituximab; E, etoposide; Bleo, bleomycin.

cristine, and prednisone) regimens (Table 2). Four patients had also surgery, and only 4 patients were treated with radiotherapy or chemo-radiotherapy. Total radiotherapy doses ranged from 30.6-40.0 Gy in 1.8-2.0 Gy/fraction.

The median survival was 163 months, and 5- and 10-year OS rates were 77% [95% confidence interval (CI): 64-90%] and 59% (95% CI: 42-76%), respectively (Figure 1). The 5- and 10-year DFS and LSS rates were 69% (95% CI: 55-83%) and 56% (95% CI: 40-72%), and 87% (95% CI: 76-98%) and 70% (95% CI: 53-87%), respectively. In univariate analyses (log rank test), patients with fever had a better outcome ($P=0.03$). There was a positive trend ($P=0.07$) for better OS in younger patients (≤ 62 years). Gender, abdominal pain or discomfort, weight loss, night sweats, preexisting liver disease, multiple or diffuse lesions, elevated liver enzymes, low hemoglobin levels, hepatosplenomegaly, histopathology, and type of treatment did not show any influence on the outcome, most probably due to the small sample size (Table 3). In multivariate analysis (Cox model), the presence of fever [relative risk (RR)=2.16; $P=0.005$], absence of weight loss (RR=1.22; $P=0.048$), and normal hemoglobin level (RR=1.07; $P=0.047$) were the independent factors influencing the outcome (Table 4).

Discussion

To our knowledge, this is one of the largest PHL series reported in the literature. PHL was first described by Ata and colleagues in 1965.¹⁰ The published articles to date are mostly case reports, and the largest series reported in the English literature are those of El-Sharkawi and colleagues¹¹ with 22 patients and Page and colleagues⁹ with 24 patients. Also there are review articles collecting and summarizing the data about pathogenesis, clinical and pathological features, and the results of treatment of PHL patients.^{2,12,13} Therefore, clinico-pathological features of patients remain unclear, and we proposed this study in an attempt to gather additional information on this rare entity through the RCN.

The age of presentation varies but PHL commonly presents in the 5th decade with a male predominance according to the published literature. In our study, median age was 62 years, which was slightly older than the literature with a male predominance. Clinical presentation is generally nonspecific. The most common presenting symptom of PHL patients is abdominal pain and the other symptoms include fatigue, weight loss, jaundice, anorexia, nausea, malaise, night sweats, and vomiting.² Abdominal pain or discomfort was the most common presenting symptom in our

patients, and occurred in more than 50% of patients. The B symptoms of fever, weight loss, and night sweats were less common. Hepatomegaly is common, and on examination can be found in at least 50% of patients;^{2,5,13} however, only 17.1% of our patients had hepatomegaly. Although enlargement of spleen by lymphomatous involvement indicates a disease process, congestive splenomegaly may occur because of hepatic dysfunction and portal hypertension in PHL patients,² and splenomegaly was less common in our series (9.8% of patients).

The etiologic factors and the pathogenesis are not clear, and there are several possible factors that have been proposed. A number of reports have suggested that PHL could evolve in patients with chronic hepatitis, cirrhosis, systemic lupus erythematosus, and in transplant patients who were being treated with immunosuppressive drugs.¹⁴⁻²⁵ Thirteen patients had a history of preexisting liver disease in our series (31.7%); 6 patients had chronic hepatitis (14.6%), 4 patients cirrhosis (9.8%), and 1 patient polycystic liver disease (2.4%); 4 patients were diagnosed after liver transplantation (9.8%). Lymphoproliferative disorders after transplantation have been developed in transplant recipients.²⁶ The possible factor is continuous B-cell proliferation, which is normally inhibited by T-lymphocytes.^{5,13} Acquired immune deficiency syndrome has also been suggested to play a role in the pathogenesis of PHL.²⁷ Two patients were Hepatitis B Ag positive and 2 patients were HIV positive among patients who were tested in our study.

PHL may radiologically present in 3 possible ways in patients: a solitary lesion, multiple lesions, or diffuse infiltration of the liver. The most common presentation in the literature is a solitary lesion, which occurs in 55-60% of patients.² In contrast to the previous reports, the majority of our patients had multiple lesions (53.7%). The complete blood count was usually within normal range when lymphoma was confined to the liver; and liver function tests, including lactate dehydrogenase, alkaline phosphatase and bilirubin, were usually elevated.¹³ Liver function tests were elevated in 56.1% of our patients who were tested. Hemoglobin levels were lower than normal limits in eleven patients.

PHL is a pathologic diagnosis. Most of the PHL cases (46-68%) reported in the literature are diffuse large B-cell lymphoma, and other histologies have been described in less than 5% of cases including diffuse mixed large and small cell, lymphoblastic, diffuse immunoblastic, diffuse histiocytic, mantle cell, and small non-cleaved or Burkitt lymphoma.^{2,5,9}

Immunohistochemistry, gene rearrangement, karyotyping, and flow cytometry help in further characterization of the tumor.² The most common histopathological diagnosis was diffuse large B-cell lymphoma, which was observed in 27 patients (65.9%) in our series. T-cell PHL is less common and the described subtypes include peripheral T-cell lymphoma, anaplastic T-cell lymphoma, and hepatosplenic T-cell lymphoma.²⁸ Three of our patients had T-cell lymphoma including two mature T-cell and small lymphocytic type T-cell lymphomas. There were also other subtypes




Figure 1. Overall survival for 41 patients with primary hepatic lymphoma.

Table 3. Univariate analyses in 41 patients with primary hepatic lymphoma.

Variable	No.	5-year OS, %	95% CI	10-year OS,%	95% CI	P value*
All patients	41	77	64-90	59	42-76	
Age						
>62	21	70	50-90	49	25-73	0.07
≤62	20	84	68-100	69	46-92	
Gender						
Male	27	77	61-93	60	39-81	0.90
Female	14	79	57-100	57	27-87	
Surgery						
Yes	4	100	-	100	-	0.12
No	37	75	61-89	56	38-74	
Hemoglobin level						
Normal	30	86	73-99	65	45-85	0.13
Lower than normal	11	55	26-85	44	14-74	
Liver function tests						
Normal	18	78	59-97	69	46-92	0.86
Elevated	23	77	59-95	52	29-75	
Radiological presentation						
Solitary	15	71	47-95	71	47-95	0.52
Multiple or diffuse	26	80	64-96	54	32-76	
Pre-existing liver disease						
Yes	13	76	52-99	63	33-93	0.86
No	28	78	62-94	58	38-79	
Splenomegaly						
Yes	4	38	0-94	38	0-94	0.37
No	37	81	68-94	61	43-79	
Hepatomegaly						
Yes	7	71	38-100	54	15-93	0.78
No	34	78	64-92	60	41-79	
Night sweats						
Yes	4	100	-	75	33-100	0.24
No	37	75	61-89	57	39-75	
Weight loss						
Yes	7	57	20-94	57	20-94	0.14
No	34	81	68-94	59	40-78	
Fever						
Yes	8	100	-	86	60-100	0.03
No	33	72	56-88	53	33-73	
B-symptoms (night sweats, weight loss, fever)						
Yes	13	77	54-99	68	42-94	0.67
No	28	78	62-94	54	32-76	
Nausea/vomiting						
Yes	7	86	60-100	57	20-94	0.55
No	34	75	60-90	61	42-80	
Anorexia						
Yes	6	67	29-100	67	29-100	0.80
No	35	79	65-93	57	38-76	
Jaundice						
Yes	6	83	53-100	83	53-100	0.88
No	35	76	62-90	54	35-73	
Fatigue						
Yes	9	78	51-100	47	10-84	0.19
No	32	77	62-92	63	44-82	
Abdominal pain or discomfort						
Yes	22	72	53-91	49	26-72	0.25
No	19	83	66-100	74	51-97	
Treatment modality						
Chemotherapy alone	26	77	61-93	61	40-82	0.59
Other	15	79	58-100	56	26-86	
Histopathology						
Diffuse large B-cell	27	81	66-96	65	45-85	0.69
Others	14	71	47-95	45	12-78	

*Log rank test. OS, overall survival; CI, confidence interval.

Table 4. Multivariate analysis in 41 patients with primary hepatic lymphoma (Cox model).

Variable	RR	SE	P-value
Fever (yes better)	2.16	1.04	0.005
Weight loss (no better)	1.22	0.57	0.048
Hemoglobin level (normal better)	1.07	0.52	0.047

RR, relative risk; SE, standard error.

including marginal zone B-cell lymphoma in 4 patients, follicular lymphoma grade 1 in 3 patients, precursor cell lymphoblastic lymphoma in 2 patients, malignant lymphoma small lymphocytic type in 1 patient, and Burkitt lymphoma in 1 patient. The tumor may have a nodular or diffuse growth pattern microscopically in which lymphoma cells expand into the liver parenchyma.²⁹

The optimal therapy is still unclear and treatment options include surgery, chemotherapy, radiation therapy, or combination of these therapies.² Surgical resection might be performed for patients with localized disease with good results.³⁰ Past indications for surgical treatment have included localized disease, which can be completely resected, or for debulking prior to chemotherapy.¹³ However, there may be a bias towards better results in patients treated surgically since they had a better performance status, preserved liver function, low volume, and no comorbidities.² Chemotherapy is the recommended treatment option for extranodal diffuse large B-cell lymphoma in general, making it a choice also for the treatment of PHL when it is diagnosed preoperatively.³¹ Chemotherapy can be used either as an adjunct to surgery or as a single modality. In a review by Avlonitis and colleagues, a median survival of 20.7 months, ranging from 10-123.6 months has been described in 14 patients treated surgically followed by adjuvant chemotherapy.¹³ Adjuvant radiation therapy, or a combination of adjuvant chemotherapy and radiation, have been utilized in some studies.³² Early and aggressive anthracycline-based combination chemotherapy may result in prolonged remissions in properly selected PHL patients.² The addition of rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, to the CHOP regimen increases the complete-response rate, and prolongs event-free and overall survival in elderly patients with diffuse large-B-cell lymphoma, without a clinically significant increase in toxicity.³³ Combination chemotherapy was administered to 30 patients (73.2%) in our study, although chemotherapy regimens differed according to the date of diagnosis and the center. The majority of patients received CHOP-like regimens.

Most of the PHL patients had poor prognos-

tic features that include advanced age, constitutional symptoms, elevated liver enzymes, and comorbid diseases.² The median survival varies considerably in the literature, and reported survival ranges from 3-123.6 months.¹³ In our study, the median survival was 163 months, which was higher than previously reported rates. In a study by Page and colleagues, reviewing the experience of MD Anderson Cancer Center, 24 PHL patients were treated with chemotherapy and the overall 5-year survival was 83%.⁹ The 5-year survival rate in our study was 77%.

The absence of fever and presence of weight loss and low hemoglobin levels were found to be the worse independent prognostic factors influencing the outcome. In univariate analyses, it is interesting to note that among the B-symptoms, fever ($P=0.03$) and night sweats ($P=0.24$) seemed to have a better influence but weight loss ($P=0.14$) a worse influence on the outcome. In general, fever is a result of immune response by the body to a foreign invader. The fever response is executed by integrated physiological and neuronal circuitry, and confers a survival benefit during infection.³⁴ A major goal of cancer immunology is to stimulate the generation of long-lasting, tumor antigen-specific immune responses that recognize and destroy tumor cells, and accumulating evidence indicates that survival benefits are accorded to individuals who achieve an increase in body temperature (*i.e.*, fever) following infection.³⁵

Conclusions

In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than those reported elsewhere. It is important to recognize this rare disease entity, as it responds to therapy, and has a better prognosis than hepatocellular carcinoma or systemic lymphomas secondarily involving the liver. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors.

References

1. Loddenkemper C, Longerich T. Lymphoma of the liver. In: Cavalli F, Stein H, Zucca E, eds. *Extranodal Lymphomas, Pathology and Management*. Abingdon, UK: CRC Press; 2008. pp 277-88.
2. Noronha V, Shafi NQ, Obando JA, Kummar S. Primary non-Hodgkin's lymphoma of the liver. *Crit Rev Oncol Hematol* 2005;53:199-207.
3. Emile JF, Azoulay D, Gornet JM, et al. Primary non-Hodgkin's lymphomas of the liver with nodular and diffuse infiltration patterns have different prognoses. *Ann Oncol* 2001;12:1005-10.
4. Lei KI, Chow JH, Johnson PJ. Aggressive primary hepatic lymphoma in Chinese patients. Presentation, pathologic features, and outcome. *Cancer* 1995;76:1336-43.
5. Lei KI. Primary non-Hodgkins lymphoma of the liver. *Leuk Lymphoma* 1998;29:293-9.
6. Chim CS, Choy C, Ooi GC, Liang R. Primary hepatic lymphoma. *Leuk Lymphoma* 2001;40:667-70.
7. Bronowicki JP, Bineau C, Feugier P, et al. Primary lymphoma of the liver: clinical-pathological features and relationship with HCV infection in French patients. *Hepatology* 2003;37:781-7.
8. DeMent SH, Mann RB, Staal SP, et al. Primary lymphomas of the liver: report of six cases and review of the literature. *Am J Clin Pathol* 1987;88:255-63.
9. Page RD, Romaguera JE, Osborne B, et al. Primary hepatic lymphoma: favorable outcome after combination chemotherapy. *Cancer* 2001;92:2023-9.
10. Ata AA, Kamel IA. Primary reticulum cell sarcoma of the liver. A case report. *J Egypt Med Assoc* 1965;48:514-21.
11. El-Sharkawi D, Ramsay A, Cwynarski K, et al. Clinico-pathologic characteristics of patients with hepatic lymphoma diagnosed using image-guided liver biopsy techniques. *Leuk Lymphoma* 2011;52:2130-4.
12. Aozasa K, Mishima K, Ohsawa M. Primary malignant lymphoma of the liver. *Leuk Lymphoma* 1993;10:353-7.
13. Avlonitis VS, Linos D. Primary hepatic lymphoma: a review. *Eur J Surg* 1999;165:725-9.
14. Lisker-Melman M, Pittaluga S, Pluda JM, et al. Primary lymphoma of the liver in a patient with acquired immune deficiency syndrome and chronic hepatitis B. *Am J Gastroenterol* 1989;84:1445-8.
15. Mohan C, Alurkar SS, Sharma OP, Advani SH. Primary liver lymphoma: a diagnostic dilemma. *AJR Am J Roentgenol*

- 1991;157:413.
16. Mohamed M, Fernando R. Diagnostic and therapeutic quandaries in a patient with primary hepatic lymphoma and concurrent hepatitis C infection. *Indian J Hematol Blood Transfus* 2014;30:394-7.
 17. Sekiguchi Y, Yoshikawa H, Shimada A, et al. Primary hepatic circumscribed Burkitt's lymphoma that developed after acute hepatitis B: report of a case with a review of the literature. *J Clin Exp Hematop* 2013;53:167-73.
 18. Somaglino C, Pramaggiore P, Polastri R. Primary hepatic lymphoma in a patient with chronic hepatitis B and C infection: diagnostic pitfalls and therapeutic challenge. *Updates Surg* 2014;66:89-90.
 19. Kikuma K, Watanabe J, Oshiro Y, et al. Etiological factors in primary hepatic B-cell lymphoma. *Virchows Arch* 2012;460:379-87.
 20. Nakayama S, Yokote T, Kobayashi K, et al. Primary hepatic MALT lymphoma associated with primary biliary cirrhosis. *Leuk Res* 2010;34:e17-20.
 21. Sato S, Masuda T, Oikawa H, et al. Primary hepatic lymphoma associated with primary biliary cirrhosis. *Am J Gastroenterol* 1999;94:1669-73.
 22. Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG. Liver involvement in systemic lupus erythematosus: case review of 40 patients. *J Rheumatol* 2008;35:2159-64.
 23. Sutton E, Malatjalian D, Hayne OA, Hanly JG. Liver lymphoma in systemic lupus erythematosus. *J Rheumatol* 1989;16:1584-8.
 24. Honda H, Franken EA Jr, Barloon TJ, Smith JL. Hepatic lymphoma in cyclosporine-treated transplant recipients: sonographic and CT findings. *AJR Am J Roentgenol* 1989;152:501-3.
 25. Palazzo JP, Lundquist K, Mitchell D, et al. Rapid development of lymphoma following liver transplantation in a recipient with hepatitis B and primary hemochromatosis. *Am J Gastroenterol* 1993;88:102-4.
 26. Rostaing L, Suc B, Fourtanier G, et al. Liver B cell lymphoma after liver transplantation. *Transplant Proc* 1995;27:1781-2.
 27. Caccamo D, Pervez NK, Marchevsky A. Primary lymphoma of the liver in the acquired immunodeficiency syndrome. *Arch Pathol Lab Med* 1986;110:553-5.
 28. Stancu M, Jones D, Vega F, Medeiros LJ. Peripheral T-cell lymphoma arising in the liver. *Am J Clin Pathol* 2002;118:574-81.
 29. Steller EJ, van Leeuwen MS, van Hillegersberg R, et al. Primary lymphoma of the liver - A complex diagnosis. *World J Radiol* 2012;4:53-7.
 30. Scoazec JY, Degott C, Brousse N, et al. Non-Hodgkin's lymphoma presenting as a primary tumor of the liver: presentation, diagnosis and outcome in eight patients. *Hepatology* 1991;13:870-5.
 31. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. *J Clin Oncol* 2005;23:5027-33.
 32. Chowla A, Malhi-Chowla N, Chidambaram A, Surick B. Primary hepatic lymphoma in hepatitis C: case report and review of the literature. *Am Surg* 1999;65:881-3.
 33. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* 2002;346:235-42.
 34. Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. *Nat Rev Immunol* 2015;15:335-49.
 35. Repasky EA, Evans SS, Dewhirst MW. Temperature matters! And why it should matter to tumor immunologists. *Cancer Immunol Res* 2013;1:210-6.